View Older Stories View More Recent Stories

Jun 12, 2025 04:45PM Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs
Jun 12, 2025 04:45PM Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
Jun 12, 2025 06:46AM Merck (MRK) Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Jun 12, 2025 06:45AM Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Jun 9, 2025 03:11PM U.S. FDA Approves Merck’s (MRK) ENFLONSIA for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
Jun 9, 2025 03:11PM U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Seaso
Jun 9, 2025 06:45AM Merck (MRK) Reports Positive Topline Results From the First Two Phase 3 CORALreef Trials
Jun 9, 2025 06:45AM Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
Jun 4, 2025 06:45AM Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
May 31, 2025 08:00AM KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Neg
May 30, 2025 08:05AM Merck (MRK) Announces MK-1084 Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
May 30, 2025 08:05AM Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbo
May 30, 2025 08:01AM Merck's (MRK) Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate
May 30, 2025 08:00AM Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBC
May 29, 2025 07:00AM Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
May 27, 2025 01:24PM Merck Announces Third-Quarter 2025 Dividend
May 22, 2025 06:45AM Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
May 19, 2025 07:01AM IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 19, 2025 07:00AM IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 16, 2025 06:45AM Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial H
May 15, 2025 06:45AM Merck (MRK) Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival
May 15, 2025 06:45AM Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All C
May 14, 2025 05:30PM Merck (MRK) announces FDA approval of WELIREG
May 14, 2025 05:15PM FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma
May 13, 2025 06:45AM Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
May 8, 2025 06:45AM Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
May 7, 2025 06:45AM Merck to Participate in the Bank of America 2025 Global Healthcare Conference
Apr 29, 2025 06:57AM Merck (MRK) Breaks Ground on New $1B Biologics Center of Excellence in Wilmington, Delaware
Apr 29, 2025 06:45AM Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
Apr 27, 2025 12:00PM KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally
Apr 24, 2025 08:34AM Halozyme Therapeutics (HALO) Sues Merck (MRK) for Patent Infringement over Subcutaneous Keytruda Formulation
Apr 24, 2025 08:00AM Curiosity Cube 2025: MilliporeSigma’s Mobile Science Labs Tour Globally to Bring STEM Education to Students
Apr 24, 2025 06:30AM Merck Announces First-Quarter 2025 Financial Results
Apr 11, 2025 12:21PM MRK IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important April 14 Deadline in Securities Class Ac
Apr 10, 2025 12:14PM MRK FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
Apr 8, 2025 02:40PM MRK DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
Apr 6, 2025 12:26PM MRK FINAL DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Clas
Apr 4, 2025 01:17PM MRK FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Actio
Apr 3, 2025 01:11PM MRK FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - M
Apr 1, 2025 06:06PM ROSEN, NATIONAL TRIAL LAWYERS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Apr 1, 2025 06:45AM Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
Mar 31, 2025 01:58PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 31, 2025 10:00AM Merck (MRK) Report WINREVAIR Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76%
Mar 31, 2025 10:00AM WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the
Mar 29, 2025 09:19AM ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 27, 2025 11:01AM Merck (MRK) Reports Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous KEYTRUDA
Mar 27, 2025 11:01AM Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77
Mar 26, 2025 06:45AM Merck (MRK) Receives EU Approval for CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
Mar 26, 2025 06:45AM European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
Mar 25, 2025 03:35PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
View More Recent Stories View Older Stories